{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:36:23Z","timestamp":1759991783294},"reference-count":65,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.2217\/17460913.3.3.251","type":"journal-article","created":{"date-parts":[[2008,5,28]],"date-time":"2008-05-28T16:17:32Z","timestamp":1211991452000},"page":"251-263","source":"Crossref","is-referenced-by-count":12,"title":["Oritavancin: A Potential Weapon in the Battle Against Serious Gram-Positive Pathogens"],"prefix":"10.1080","volume":"3","author":[{"given":"Jared","family":"Crandon","sequence":"first","affiliation":[{"name":"Center for Anti-Infective Research & Development,Hartford Hospital,\r80 Seymour Street,\rHartford,\rCT 06102,\rUSA. Tel: ; Fax: ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research & Development,Hartford Hospital,\r80 Seymour Street,\rHartford,\rCT 06102,\rUSA Tel: ; Fax: ; and, Division of Infectious Diseases,Hartford Hospital,Hartford,CT,USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2008,5,28]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.1086\/375081"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.19.2223"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.5.522"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2004.10.001"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2006.01344.x"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/524891"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0400277101"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2003.tb00628.x"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.49.575"},{"key":"e_1_3_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2008.01.031"},{"key":"e_1_3_2_3_11_1","volume-title":"47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"Wang T-SA","unstructured":"Wang T-SA , KahneDE, WalkerS: Probing the mechanism of inhibition of bacterial peptidoglycan glycotransferases by glycopeptide analogs. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, Chicago, IL, USA, 17\u201320 September, 2007. (Abstract C1\u20131474)."},{"key":"e_1_3_2_3_12_1","volume-title":"46th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"McKay G","unstructured":"McKay G , FadhilI, BeaulieuSet al.: Oritavancin disrupts transmembrane potential and membrane integrity concomitantly with cell killing in Staphylococcus aureus and vancomycin-resistant enterococci. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, San Francisco, CA, USA, 17\u201320 September, 2006. (Abstract C1\u2013682)."},{"key":"e_1_3_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.9.2452"},{"key":"e_1_3_2_3_14_1","volume-title":"47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"O\u2018Connor R","unstructured":"O\u2018Connor R , BainesS, FreemanJ, WilcoxM: In vitro susceptibility of genotypically distinct Clostridium difficile strains to oritavancin. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, Chicago, IL, USA, 17\u201320 September, 2007. (Abstract E-1618)."},{"key":"e_1_3_2_3_15_1","volume-title":"47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"Arhin F","unstructured":"Arhin F , SarmientoI, BalleyAet al.: Activity of oritavancin against drug-resistant S. aureus in the presence of polysorbate-80. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, Chicago, IL, USA, 17\u201320 September, 2007. (Abstract D-242)."},{"key":"e_1_3_2_3_16_1","volume-title":"47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"Sahm DF","unstructured":"Sahm DF , ArhinFF, MoeckG, DraghiD: In vitro activity profile of oritavancin against resistant staphylococcal populations from a recent surveillance initiative. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, Chicago, IL, USA, 17\u201320 September, 2007. (Abstract E-1617)."},{"key":"e_1_3_2_3_17_1","volume-title":"47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"Draghi DC","unstructured":"Draghi DC , GroverPK, MoeckGet al.: In vitro activity profile of oritavancin (ORI) against organisms demonstrating key resistance profiles to other antimicrobial agents. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, Chicago, IL, USA, 17\u201320 September, 2007. (Abstract E-1613)."},{"key":"e_1_3_2_3_18_1","volume-title":"47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"Draghi DC","unstructured":"Draghi DC , SahmDF, ArhinFF, MoeckG: Anti-streptococcal activity profile of oritavancin, a potent lipoglycopeptide under development for use against Gram-positive infections. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, Chicago, IL, USA, 17\u201320 September, 2007. (Abstract E-1616)."},{"key":"e_1_3_2_3_19_1","volume-title":"47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"Draghi D","unstructured":"Draghi D , SahmDF, ArhinFF, MoeckG: Anti-enterococcal activity profile of oritavancin, a potent lipoglycopeptide under development for use against Gram-positive infections. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, Chicago, IL, USA, 17\u201320 September, 2007. (Abstract E-1615)."},{"key":"e_1_3_2_3_20_1","volume-title":"47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"Moeck G","unstructured":"Moeck G , DraghiD, ArhinF, SahmD: In vitro activity profile of oritavancin against a broad spectrum of aerobic and anaerobic bacterial pathogens. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, Chicago, IL, USA, 17\u201320 September, 2007. (Abstract E-1612)."},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01513-07"},{"key":"e_1_3_2_3_22_1","volume-title":"17th European Congress of Clinical Microbiology and Infectious Diseases Abstracts.","author":"Arhin F","unstructured":"Arhin F , SarmientoI, BalleyA, McKayG: Influence of polysorbate-80 on susceptibility of Gram-positive bacteria to oritavancin. Presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases Abstracts.European Society of Clinical Microbiology and Infectious Diseases, Munich, Germany, March 31\u2013April 4, 2007. (Abstract P827)."},{"key":"e_1_3_2_3_23_1","unstructured":"Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing . Seventeenth Informational Supplement. CLSI document M100-S18. CLSI PA USA (2008)."},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg457"},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.4.981"},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.1.115"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.3017-3021.2000"},{"key":"e_1_3_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.5.705"},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.7.2169-2172.2001"},{"key":"e_1_3_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.6.1907-1911.2003"},{"key":"e_1_3_2_3_31_1","volume-title":"47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"Lehoux D","year":"2007","unstructured":"Lehoux D , OkusanyaO, OstiguyVet al.: PK\u2013PD of oritavancin against S. pneumoniae in a murine-pneumonia infection model. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, Chicago, IL, USA, 17\u201320September, 2007. (Abstract A-49)."},{"key":"e_1_3_2_3_32_1","volume-title":"47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"Bhavnani S","year":"2007","unstructured":"Bhavnani S , RubinoC, ForrestAet al.: Use of PK\u2013PD principles to guide clinical drug development for oritavancin. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, Chicago, IL, USA, 17\u201320September, 2007. (Abstract A-51)."},{"key":"e_1_3_2_3_33_1","volume-title":"38th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"Chien J","year":"1998","unstructured":"Chien J , AllerheiligenS, PhillipsDet al.: Safety and pharmacokinetics of single intravenous doses of ly333328 diphosphate (glycopeptide) in healthy men. Presented at: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, San Diego, CA, USA, 24\u201327September, 1998. (Abstract A-55)."},{"key":"e_1_3_2_3_34_1","volume-title":"12th European Congress of Clinical Microbiology and Infectious Diseases Abstracts.","author":"De la Pena A","year":"2002","unstructured":"De la Pena A , ChienJ, GeiserJet al.: Microbiological outcomes and pharmacokinetics of oritavancin in patients with Gram-positive bacteremia. Presented at: 12th European Congress of Clinical Microbiology and Infectious Diseases Abstracts.European Society of Clinical Microbiology and Infectious Diseases, Milan, Italy, 21\u201324April, 2002. (Abstract P1091)."},{"key":"e_1_3_2_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2004.06.007"},{"key":"e_1_3_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.148-152.2005"},{"key":"e_1_3_2_3_37_1","volume-title":"11th European Congress of Clinical Microbiology and Infectious Diseases Abstracts.","author":"Braun D","year":"2001","unstructured":"Braun D , ChienJ, RarlowDet al.: Oritavancin (LY333328): a dose-escalation safety and pharmacokinetics study in patients. Presented at: 11th European Congress of Clinical Microbiology and Infectious Diseases Abstracts.European Society of Clinical Microbiology and Infectious Diseases, Istanbul, Turkey1\u20134April, 2001."},{"key":"e_1_3_2_3_38_1","volume-title":"41st Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"Rowe PA","unstructured":"Rowe PA , BrownTJ: Protein binding of 14C-oritavancin. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, Chicago, IL, USA, 16\u201319 December, 2001. (Abstract A-2193)."},{"key":"e_1_3_2_3_39_1","volume-title":"41st Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"Van Bambeke F","unstructured":"Van Bambeke F , CarrynS, SnoeckAet al.: LY333328 (oritavancin) glycopeptide accumulates in cultured macrophages but is only bacteriostatic towards intracellular Listeria monocytogenes. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, Chicago, IL, USA, 16\u201319 December, 2001. (Abstract A-2069)."},{"key":"e_1_3_2_3_40_1","volume-title":"11th European Congress of Clinical Microbiology and Infectious Diseases Abstracts.","author":"Van Bambeke F","year":"2001","unstructured":"Van Bambeke F , SnoeckA, Chanteuxet al.: Is LY33328 glycopeptide a new cell-associated antibiotic? Comparative studies with vancomycin and azithromycin in a model of J774 mouse macrophages. Presented at: 11th European Congress of Clinical Microbiology and Infectious Diseases Abstracts.European Society of Clinical Microbiology and Infectious Diseases, Istanbul, Turkey1\u20134April, 2001."},{"key":"e_1_3_2_3_41_1","volume-title":"42nd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"Seral C","year":"2002","unstructured":"Seral C , Van BambekeF, TulkensP: Activity of the new glycopeptide oritavancin (LY333328) in a model of Staphylococcus aureus intraphagocytic infection in comparison with telithromycin (TEL) and moxifloxacin (MXF). Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, San Diego, CA, USA, 27\u201330September, 2002. (Abstract A-483)."},{"key":"e_1_3_2_3_42_1","volume-title":"43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"Barcia-Macay M","year":"2003","unstructured":"Barcia-Macay M , SeralC, Mingeot-LeclercqMet al.: Comparative activity of 12 antibiotics (abx) used at clinically-meaningful extracellular concentration against S. aureus in broth and in human thp-1 macrophages. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, Chicago, IL, USA14\u201317September, 2003. (Abstract A-1174)."},{"key":"e_1_3_2_3_43_1","volume-title":"14th European Congress of Clinical Microbiology and Infectious Diseases Abstracts.","author":"Rodvold K","unstructured":"Rodvold K , GotfriedM, LoutitJ, PorterS: Plasma and intrapulmonary concentrations of oritavancin and vancomycin in normal healthy adults. Presented at: 14th European Congress of Clinical Microbiology and Infectious Diseases Abstracts.European Society of Clinical Microbiology and Infectious Diseases, Prague\/Czech Republic 1\u20134 May, 2004. (Abstract O254)."},{"key":"e_1_3_2_3_44_1","volume-title":"The American Association of Pharmaceutical Scientists Annual Meeting Abstracts.","author":"Fetterly G","unstructured":"Fetterly G , OwenJ, BhavnaniSet al.: Effect of hepatic impairment on the pharmacokinetics of the novel glycopeptide oritavancin. Presented at: The American Association of Pharmaceutical Scientists Annual Meeting Abstracts.The American Association of Pharmaceutical Scientists, Baltimore, MD, USA, 7\u201310 November, 2004. (Abstract T3313)."},{"key":"e_1_3_2_3_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.6.1307"},{"key":"e_1_3_2_3_46_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.10.2165"},{"key":"e_1_3_2_3_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.6.1407"},{"key":"e_1_3_2_3_48_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.706-709.2001"},{"key":"e_1_3_2_3_49_1","volume-title":"43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"Sahm D","unstructured":"Sahm D , BlosserR, LoutitJ, PorterS: Oritavancin time-kill, time-kill synergy, and postantibiotic effect determinations with S. aureus and enterococci. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, Chicago, IL, USA, 14\u201317 September, 2003. (Abstract A-1170)."},{"key":"e_1_3_2_3_50_1","volume-title":"47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"McKay G","unstructured":"McKay G , BeaulieuS, BelleyAet al.: In vitro time kill studies of oritavancin against drug-resistant isolates of Staphylococcus aureus and Enterococci. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, Chicago, IL, USA, 17\u201320 September, 2007. (Abstract E-1614)."},{"key":"e_1_3_2_3_51_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1700-1706.2003"},{"key":"e_1_3_2_3_52_1","volume-title":"38th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"Rupp M","unstructured":"Rupp M , UlphaniJ: Efficacy of LY333328 in a rat model of Staphylococcus aureus (SA) central venous catheter (CVC)-associated infection. Presented at: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, San Diego, CA, USA, 24\u201327 September, 2008. (Abstract F-111)."},{"key":"e_1_3_2_3_53_1","volume-title":"47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"Lehoux D","unstructured":"Lehoux D , OkusanyaO, OstiguyVet al.: PK\u2013PD of oritavancin against S. pneumoniae in a murine-pneumonia infection model. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, Chicago, IL, USA, 17\u201320 September, 2007. (Abstract A-49)."},{"key":"e_1_3_2_3_54_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.3017-3021.2000"},{"key":"e_1_3_2_3_55_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.3.994-1000.2006"},{"key":"e_1_3_2_3_56_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.770-772.2005"},{"key":"e_1_3_2_3_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.2991-2998.2000"},{"key":"e_1_3_2_3_58_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.10.2564"},{"key":"e_1_3_2_3_59_1","volume-title":"47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"McKay G","unstructured":"McKay G , BeaulieuS, ParrTJr, MoeckG: In vitro post antibiotic effect studies of oritavancin against S. aureus and enterococci. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, Chicago, IL, USA, 17\u201320 September, 2007. (Abstract A-50)."},{"key":"e_1_3_2_3_60_1","volume-title":"46th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"Belley A","unstructured":"Belley A , McKayG, BeaulieuSet al.: Oritavancin kills Staphylococcus aureus in slow-growing planktonic and biofilm states. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, San Francisco, CA, USA, 17\u201320 September, 2006. (Abstract B-0661)."},{"key":"e_1_3_2_3_61_1","volume-title":"47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"Belley A","unstructured":"Belley A , Neesham-GrenonE, ParrTJr, MoeckG: Pharmacokinetic concentrations of oritavancin kill stationary-phase and biofilm Staphylococcus aureusin vitro. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, Chicago, IL, USA, 17\u201320 September, 2007. (Abstract E-1620)."},{"key":"e_1_3_2_3_62_1","volume-title":"41st Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"Wasilewski M","year":"2001","unstructured":"Wasilewski M , DischD, McGillJet al.: Equivalence of shorter course therapy with oritavancin vs. vancomycin\/cephalexin in complicated skin\/skin structure infections. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, Chicago, IL, USA, 16\u201319December, 2001. (Abstract UL-18)."},{"key":"e_1_3_2_3_63_1","volume-title":"43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.","author":"Giamarellou G","unstructured":"Giamarellou G , O\u2018RiordanW, HarrisH, et al.: Phase 3 trial comparing 3\u20137 days of oritavancin vs. 10\u201314 days of vancomycin\/cephalexin in the treatment of patients with complicated skin and skin structure infections. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts.American Society for Microbiology, Chicago, IL, USA 14\u201317 September, 2003. (Abstract L-739a)."},{"key":"e_1_3_2_3_64_1","volume-title":"14th European Congress of Clinical Microbiology and Infectious Diseases Abstracts.","author":"Loutit J","unstructured":"Loutit J , O\u2018RiordanW, San JuanJet al.: Phase 2 trial comparing four regimens of oritavancin vs. comparator in the treatment of patients with S. aureus bacteremia. Presented at: 14th European Congress of Clinical Microbiology and Infectious Diseases Abstracts.European Society of Clinical Microbiology and Infectious Diseases, Prague\/Czech Republic, 1\u20134 May, 2004. (Abstract P541)."},{"key":"e_1_3_2_3_65_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1695-1700.2005"}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/17460913.3.3.251","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:38:31Z","timestamp":1719124711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/17460913.3.3.251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,28]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.2217\/17460913.3.3.251"],"URL":"https:\/\/doi.org\/10.2217\/17460913.3.3.251","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,28]]}}}